Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections

被引:76
|
作者
Andeweg, Stijn P. [1 ]
de Gier, Brechje [1 ]
Eggink, Dirk [1 ]
van den Ende, Caroline [1 ]
van Maarseveen, Noortje [2 ,3 ]
Ali, Lubna [2 ]
Vlaemynck, Boris [4 ]
Schepers, Raf [4 ]
Hahne, Susan J. M. [1 ]
Reusken, Chantal B. E. M. [1 ]
de Melker, Hester E. [1 ]
van den Hof, Susan [1 ]
Knol, Mirjam J. [1 ]
机构
[1] Ctr Infect Dis Control, Natl Inst Publ Hlth & Environm RIVM, Bilthoven, Netherlands
[2] Saltro Diagnost Ctr Primary Care, Utrecht, Netherlands
[3] Univ Med Ctr Utrecht, Dept Med Microbiol, Utrecht, Netherlands
[4] SYNLAB, Heppignies, Belgium
关键词
D O I
10.1038/s41467-022-31838-8
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The protection of COVID-19 vaccines against emerging variants needs to be monitored. Here, the authors use community testing data from the Netherlands and find that protection against infection by Omicron subvariants BA.1 and 2 is low and that booster vaccines considerably but temporarily increase protection. Given the emergence of the SARS-CoV-2 Omicron BA.1 and BA.2 variants and the roll-out of booster COVID-19 vaccination, evidence is needed on protection conferred by primary vaccination, booster vaccination and previous SARS-CoV-2 infection by variant. We employed a test-negative design on S-gene target failure data from community PCR testing in the Netherlands from 22 November 2021 to 31 March 2022 (n = 671,763). Previous infection, primary vaccination or both protected well against Delta infection. Protection against Omicron BA.1 infection was much lower compared to Delta. Protection was similar against Omicron BA.1 compared to BA.2 infection after previous infection, primary and booster vaccination. Higher protection was observed against all variants in individuals with both vaccination and previous infection compared with either one. Protection against all variants decreased over time since last vaccination or infection. We found that primary vaccination with current COVID-19 vaccines and previous SARS-CoV-2 infections offered low protection against Omicron BA.1 and BA.2 infection. Booster vaccination considerably increased protection against Omicron infection, but decreased rapidly after vaccination.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2
    Fiaschi, Lia
    Dragoni, Filippo
    Schiaroli, Elisabetta
    Bergna, Annalisa
    Rossetti, Barbara
    Giammarino, Federica
    Biba, Camilla
    Gidari, Anna
    Lai, Alessia
    Nencioni, Cesira
    Francisci, Daniela
    Zazzi, Maurizio
    Vicenti, Ilaria
    VIRUSES-BASEL, 2022, 14 (07):
  • [42] Household transmission of SARS-CoV-2 Omicron variant of concern subvariants BA.1 and BA.2 in Denmark
    Frederik Plesner Lyngse
    Carsten Thure Kirkeby
    Matthew Denwood
    Lasse Engbo Christiansen
    Kåre Mølbak
    Camilla Holten Møller
    Robert Leo Skov
    Tyra Grove Krause
    Morten Rasmussen
    Raphael Niklaus Sieber
    Thor Bech Johannesen
    Troels Lillebaek
    Jannik Fonager
    Anders Fomsgaard
    Frederik Trier Møller
    Marc Stegger
    Maria Overvad
    Katja Spiess
    Laust Hvas Mortensen
    Nature Communications, 13
  • [43] Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2
    Hu, Bingjie
    Chan, Jasper Fuk-Woo
    Liu, Huan
    Liu, Yuanchen
    Chai, Yue
    Shi, Jialu
    Shuai, Huiping
    Hou, Yuxin
    Huang, Xiner
    Yuen, Terrence Tsz-Tai
    Yoon, Chaemin
    Zhu, Tianrenzheng
    Zhang, Jinjin
    Li, Wenjun
    Zhang, Anna Jinxia
    Zhou, Jie
    Yuan, Shuofeng
    Zhang, Bao-Zhong
    Yuen, Kwok-Yung
    Chu, Hin
    EMERGING MICROBES & INFECTIONS, 2022, 11 (01) : 2275 - 2287
  • [44] Co-infection with SARS-CoV-2 omicron BA.1 and BA.2 subvariants in a non-vaccinated woman
    Vatteroni, Maria Linda
    Capria, Anna-Lisa
    Spezia, Pietro Giorgio
    Frateschi, Susi
    Pistello, Mauro
    LANCET MICROBE, 2022, 3 (07): : E478 - E478
  • [45] SARS-CoV-2 Serology Did Not Predict Risk of Breakthrough Infection During the Omicron BA.1 and BA.2 Surge
    Bruxvoort, Katia J.
    Shi, Jiaxiao
    Song, Hubert
    Narwaney, Komal
    Glanz, Jason M.
    Binswanger, Ingrid
    Lam, Jessica A.
    Chang, John M.
    Portugal, Cecilia
    Watanabe, Cheryl
    Aragones, Michael
    Palmer-Toy, Darryl E.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2024, 148 (01) : 7 - 11
  • [46] Convalescent Plasma Therapy in Immunocompromised Patients Infected With the BA.1 or BA.2 Omicron SARS-CoV-2
    Richier, Quentin
    De Valence, Benjamin
    Chopin, Dorothee
    Gras, Emmanuelle
    Levi, Laura I.
    Aad, Yasmine Abi
    Pacanowski, Jerome
    Meynard, Jean-Luc
    Placais, Leo
    Fey, Dorothee
    Couture, Priscille
    Martin-Blondel, Guillaume
    Pestre, Vincent
    Woessner, Juliette
    Ancellin, Sophie
    Weyrich, Pierre
    Carpentier, Benjamin
    Idri, Salim
    Tiberghien, Pierre
    Surgers, Laure
    Hueso, Thomas
    Lacombe, Karine
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2024, 18 (03)
  • [47] Household transmission of SARS-CoV-2 Omicron variant of concern subvariants BA.1 and BA.2 in Denmark
    Lyngse, Frederik Plesner
    Kirkeby, Carsten Thure
    Denwood, Matthew
    Christiansen, Lasse Engbo
    Molbak, Kare
    Moller, Camilla Holten
    Skov, Robert Leo
    Krause, Tyra Grove
    Rasmussen, Morten
    Sieber, Raphael Niklaus
    Johannesen, Thor Bech
    Lillebaek, Troels
    Fonager, Jannik
    Fomsgaard, Anders
    Moller, Frederik Trier
    Stegger, Marc
    Overvad, Maria
    Spiess, Katja
    Mortensen, Laust Hvas
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [48] Determinants of Spike infectivity, processing, and neutralization in SARS-CoV-2 Omicron subvariants BA.1 and BA.2
    Pastorio, Chiara
    Zech, Fabian
    Noettger, Sabrina
    Jung, Christoph
    Jacob, Timo
    Sanderson, Theo
    Sparrer, Konstantin M. J.
    Kirchhoff, Frank
    CELL HOST & MICROBE, 2022, 30 (09) : 1255 - +
  • [49] Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study
    He, Xiaofeng
    Zeng, Biao
    Wang, Ye
    Pang, Yulian
    Zhang, Meng
    Hu, Ting
    Liang, Yuanhao
    Kang, Min
    Tang, Shixing
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [50] Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections
    Miyashita, Naoyuki
    Nakamori, Yasushi
    Ogata, Makoto
    Fukuda, Naoki
    Yamura, Akihisa
    Ishiura, Yoshihisa
    Ito, Tomoki
    VIRUSES-BASEL, 2023, 15 (06):